1. Y. Anjaneyulu, and R. Marayya. Quality assurance
and quality management in pharmaceutical
industry, Pharmamed press, Hyderabad, 2009, pp.
1-7.
2. J. Biolos. Six sigma meets the service economy-six
sigma: it’s not just for
manufacturing,Harv.Manag.Updat. 7: 3-5 (2002).
3. J. M. Caudron, N. Ford, M. Henkens, C. Mace, R.
Kiddle-Monroe, and J. Pinel. Substandard medicines
in resource-poor settings: a problem that can no
longer be ignored, Trop. Med. Int. Health13
(8):1062-1072(2008).
4. P. N. Newton. Counterfeit anti-infective drugs,
Lancet. Infect. Dis 6(9): 602-613 (2006).
5. E. Wondemagegnehu. Counterfeit and substandard
drugs in Myanmar and Viet Nam. Geneva, World
Health Organization (1999).
6. N. Dubey, R.Sharma, H. Gupta, N. Dubey, and N.
Dubey. Pharmaceutical Quality Management
System: Current Concept, J. Adv. Pharm.Edu.Res
1(2):120-124 (2011).
7. G. Isaac, C. S. Rajendran, and R. N. Anantharaman.
Significance of quality certification: The case of the
software industry in India, Qual. Manage. J. 11 (1):
8-32 (2004).
8. J. P. Corrigan, The art of TQM, Qual. Prog. 28 (7): 61-
66 (1995).
9. J. E. Enders. Quality assurance and control. In:
Gennaro AR. (Ed.). Remington: The Science and
Practice of Pharmacy, Lippincott Williams &
Wilkins, New York, 200, pp. 980-985.
10. L. Lachman, S. A. Hanna,and K. Lin. Quality control
and assurance. In: Lachman. L, Lieberman HA, Kanig
JL. (Eds.). The Theory and Practice of Industrial
Pharmacy, Varghese Publishing House, Bombay-
India, 1976, pp. 804-855.
11. X. Y. Lawrence. US FDA question-based review for
generic drugs: A new pharmaceutical quality
assessment system,Journal of Generic Medicines:
The Business Journal for the Generic Medicines
Sector 4(4): 239-246 (2007).
12. P. H. Calcott. How QbD and the FDA Process
Validation Guidance Affect Product Development
and Operations, Part, BioProcess International
9(10):12-17 (2011).
13. C. S. Kumar, and R. Panneerselvam. Literature
review of JIT-KANBAN system. The Int. J. Manuf.
Technol. 32(3-4):393-408 (2007).
14. Y. Dallery, and S. B. Gershwin. Manufacturing flow
line systems: A review of models and analytical
results,QueueingSyst. 12(1-2):3-94 (1992).
15. M. Colledani, and T.Tolio. A decomposition method
to support the configuration/ reconfiguration of
production systems, CIRP Ann. Manuf.Technol.
54(1): 441-444 (2005).
16. R. A. Lionberger, S. L. Lee, L. Lee, A. Raw, and X. Y.
Lawrence. Quality by design: concepts for ANDAs,
AAPS J. 10(2):268-276 (2008).
17. S. Jain. Mechanical properties of powders for
compaction and tableting: An overview. Pharma.
Sci. Technol. Today 2(1):20-31 (1999).
18. World Health Organization. Application of hazard
analysis and critical control point (HACCP)
methodology to pharmaceuticals (Annex 7), WHO
Expert Committee on Specifications for
Pharmaceutical Preparations (2003).
19. G. S. Banker, A. Y. Gore, and J. Swarbrick. Water
vapour transmission properties of applied polymer
films, J. Pharm. Pharmacol. 18 (S1): 205S-211S
(1966).
20. F. Boukouvala, F. J. Muzzio, and M. G. Ierapetritou.
Design space of pharmaceutical processes using
data-driven-based methods, J. Pharm.Innov.
5(3):119-137 (2010).
21. C. Chen. Implementing quality by design: ONDQA
initiatives. Advisory Committee for Pharmaceutical
Science [online]. 2006 [cited 2014 November 5];
Available from: http://www.fda.gov/ohrms
/dockets/ac/06/slides /2006– 4241s1-index.htm.
22. R. A. Lionberger, S. L. Lee, L. Lee, A. Raw, and X. Y.
Lawrence. Quality by design: concepts for ANDAs,
AAPS J. 10(2):268-276 (2008).
Ashish Baldi et al., ARPB, 2015; Vol 5 (I) ISSN 2250-0774
(INVITED REVIEW)
811 | P a g e w w w . a r p b . i n f o
23. W. P. Ganzer, J. A. Materna, M. B. Mitchell, and L.
K.Wall. Current thoughts on critical process
parameters and API synthesis [online]. 2005 [cited
2014 November 5]; Available from:
http://www.pharmtech.com/node/239694.
24. M. H. Safizadeh, L. P. Ritzman, D. Sharma,and C.
Wood, An empirical analysis of the product-process
matrix, Manag. Sci.42 (11): 1576–1591 (1996).
25. E. Davis, and M. Ierapetritou. A kriging based
method for the solution of mixed-integer nonlinear
programs containing black-box functions, J. Global
Optimiz. 43(2-3):191-205 (2009).
26. S. Curry, R. Brown. The target product profile as a
planning tool in drug discovery research,
Pharmatech. 67-71 (2003).
27. FDA CDER. Draft guidance for industry. Q8
pharmaceutical development, version 4.3 (draft),
Nov, 2004.
28. J. Antony. Six sigma for service processes, Bus.
Process Manag. J. 12(2): 234-248 (2006).
29. J. Antony, F. J. Antony, M. Kumar, and B. R. Cho. Six
sigma in service organizations: Benefits, challenges
and difficulties, Common myths, empirical
observations and success factors, Int. J. Qua. Rel.
Mgt. 24(3): 294-311(2007).
30. R. L. Edgeman, D. Bigio, and T. Ferleman. Six sigma
and business excellence: strategic and tactical
examination of IT service level management at the
Office of the Chief Technology Officer of
Washington, DC, Qual. Reliab. Eng. Int. 21(3): 257-
273 (2005).
31. T. N. Goh. A strategic assessment of six sigma, Qual.
Reliab. Eng.Int, 18(5): 403-410 (2002).
32. G. Wessel, and P. Burcher. Six sigma for small and
medium-sized enterprises, The TQM Magazine
16(4): 264-272 (2004).
33. T. Chakrabarty, and K. C. Tan. The current state of
six sigma application in services, Managing Service
Quality: An International Journal 17(2):194-208
(2007).
34. World Health Organization. The UNICEF-UNDPWorld
Bank-WHO Special Programme for research
and training in Tropical Diseases-TDR, WHO
[online]. 1975 [cited 2014 Apr 4]; Available from:
http://www.who.int/trypanosomiasis_african/part
ners/tdr/en/.
35. International Conference on Harmonisation
Working Group. ICH harmonised tripartite
guideline: guideline for good clinical practice E6
(R1), In International Conference on Harmonisation
of Technical Requirements for Registration of
Pharmaceuticals for Human Use 10 (1996).
36. Food and Drug Administration. CFR-Code of Food
Regulations Title 2, Parts 210 and 211, FDA
[online]. 1996 [cited 2014 Apr 4]; Available from:
http://www.accessdata.fda.gov/scripts/cdrh/cfdoc
s/cfcfr/CFRSearch.cfm?CFRPart=210
http://www.accessdata.fda.gov/scripts/cdrh/cfdoc
s/cfcfr/CFRSearch.cfm?CFRPart=211.
37. World Health Organization. Good distribution
practices (GDP) for pharmaceutical products, WHO
[online]. 2005 [cited 2014 Apr 4]; Available
from:http://www.who.int/medicines/services/exp
ertcommittees/pharmprep/QAS_068Rev2_GDPdraf
t.pdf
38. World Health Organization, WHO Technical Report
Series, No. 957, Annex 5, WHO good distribution
practices for pharmaceutical products. 235- 264
(2010).
39. Q10 Pharmaceutical Quality System, U.S.
Department of Health and Human Services Food
and Drug Administration Centre for Drug
Evaluation and Research (CDER) Centre for
Biologics Evaluation and Research(CBER), p. 2-19,
2009.
40. L. Lakhal, F. Pasin, M. Limam. Quality management
practices and their impact on performance.Int. J.
Qua. Rel. Mgt. 23(6): 625-646 (2006).
41. A. Moy, EMEA and FDA approaches on the ICH Q10
on pharmaceutical quality system, Pharma Times
41(8) :15-18, 2009.
42. International Conference on Harmonisation
Working Group [website] [cited 2014 Apr 4];
Available from:http://www.ich.org/home.html.
Thank you for copying data from http://www.arastirmax.com
